Milestone Pharmaceuticals Reports Q3 2025 Financial Results
Milestone Pharmaceuticals ( (MIST) ) has released its Q3 earnings. Here is a breakdown of the information Milestone Pharmaceuticals presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Milestone Pharmaceuticals Inc. is a biopharmaceutical company based in Montréal, Canada, primarily focused on developing cardiovascular medicines, with its lead product candidate being etripamil, a rapid-onset nasal spray designed to treat various cardiovascular conditions. In its latest earnings report for the quarter ended September 30, 2025, Milestone Pharmaceuticals reported no revenue, consistent with its focus on research and development phases. The company experienced a net loss of $11.9 million for the quarter, with significant investments in research, development, and commercialization efforts for etripamil. The company’s cash and cash equivalents increased to $46.7 million, supported by a recent public offering that raised $48.6 million, reflecting a strategic focus on securing financial resources for ongoing operations. Despite the financial losses, Milestone Pharmaceuticals remains committed to advancing its clinical trials and securing regulatory approvals for etripamil, with management expressing confidence in the company’s ability to sustain operations over the next 12 months.
